Related Experiment Video
Updated: Jan 5, 2026

A Duplex Digital PCR Assay for Simultaneous Quantification of the Enterococcus spp. and the Human Fecal-associated HF183 Marker in Waters
Published on: March 9, 2016
A Four Marker Digital PCR Toolkit for Detecting Heavy Alcohol Consumption and the Effectiveness of Its Treatment
Robert Philibert1,2, Shelly Miller1, Amanda Noel1
1Behavioral Diagnostics LLC, Coralville, IA, USA.
Insights
New digital PCR assays can detect heavy alcohol consumption (HAC) and monitor treatment response. Methylation markers show promise for clinical use in substance use disorder treatment and wellness programs.
Area of Science:
- Biomarkers
- Genetics
- Forensic Medicine
Background:
- Heavy alcohol consumption (HAC) presents challenges for forensic, medical, and insurance sectors.
- Current clinical tools for detecting HAC and monitoring treatment are limited.
- Previous research indicated methylation-sensitive digital PCR assays (MSdPCR) show potential for HAC classification.
Purpose of the Study:
- To expand on previous findings by validating MSdPCR assays in a larger cohort.
- To assess the utility of MSdPCR for detecting current heavy alcohol consumption.
- To evaluate the potential of MSdPCR for monitoring alcohol treatment response.
Main Methods:
- Utilized data and biomaterials from 143 participants with current HAC and 200 abstinent controls.
- Developed and validated a set of 4 digital PCR (dPCR) assays.
- Analyzed methylation status changes at specific loci (e.g., cg04987734) during enforced abstinence.
Main Results:
- The 4 dPCR assays achieved an ROC AUC of 0.96 for detecting HAC.
- Methylation at cg04987734 reverted to baseline values after approximately 21 days of inpatient abstinence.
- This reversion pattern was also observed in a smaller prior study associated with treatment-induced abstinence.
Conclusions:
- Clinically implementable dPCR tools can effectively detect HAC.
- These dPCR assays show promise for monitoring the effectiveness of alcohol treatment.
- Potential applications include substance use disorder treatment, employee wellness programs, and insurance underwriting.
Abstract:
Background.-Heavy alcohol consumption (HAC) is a shared concern of the forensic, medical and insurance underwriting communities. Unfortunately, there is a relative lack of clinically employable tools for detecting HAC and monitoring treatment response. Building on the results of 3 genome wide methylation studies, we have previously shown in a small group of samples that methylation sensitive digital PCR assays (MSdPCR) have the potential to accurately classify individuals with respect to HAC in a small set of individuals. Objective.-We now expand on those earlier findings using data and biomaterials from 143 participants with current HAC and 200 abstinent controls. Results.-We show that a set of 4 digital PCR assays that have a receiver operating characteristic (ROC) area under the curve (AUC) of 0.96 for detecting those with HAC. After a mean of 21 days of inpatient enforced abstinence, methylation status at one of these markers, cg04987734, began to revert to baseline values. Re-examination of methylation data from our smaller 2014 study with respect to this locus demonstrated a similarly significant reversion pattern at cg04987734 in association with treatment enforced abstinence. Conclusions.-We conclude that clinically implementable dPCR tools can sensitively detect the presence of HAC and that they show promise for monitoring alcohol treatment results. These dPCR tools could be useful to clinicians and researchers in monitoring those enrolled in substance use disorder treatment, employee wellness programs and insurance underwriting.
More Related Videos
07:31Murine Drinking Models in the Development of Pharmacotherapies for Alcoholism: Drinking in the Dark and Two-bottle Choice
Published on: January 7, 2019
08:23Single Droplet Digital Polymerase Chain Reaction for Comprehensive and Simultaneous Detection of Mutations in Hotspot Regions
Published on: September 25, 2018